146 related articles for article (PubMed ID: 15266095)
1. Serum CA125: a tumor marker for monitoring response to treatment and follow-up in patients with non-Hodgkin's lymphoma.
Zidan J; Hussein O; Basher W; Zohar S
Oncologist; 2004; 9(4):417-21. PubMed ID: 15266095
[TBL] [Abstract][Full Text] [Related]
2. Limited usefulness of CA125 measurement in the management of Hodgkin's and non-Hodgkin's lymphoma.
Bonnet C; Beguin Y; Fassotte MF; Seidel L; Luyckx F; Fillet G
Eur J Haematol; 2007 May; 78(5):399-404. PubMed ID: 17419741
[TBL] [Abstract][Full Text] [Related]
3. A new serologic index for low-grade non-Hodgkin's lymphoma based on initial CA125 and LDH serum levels.
Benboubker L; Valat C; Linassier C; Cartron G; Delain M; Bout M; Fetissof F; Lefranq T; Lamagnere JP; Colombat P
Ann Oncol; 2000 Nov; 11(11):1485-91. PubMed ID: 11142490
[TBL] [Abstract][Full Text] [Related]
4. Serum CA 125 as a prognostic factor in non-Hodgkin's lymphoma.
Bairey O; Blickstein D; Stark P; Prokocimer M; Nativ HM; Kirgner I; Shaklai M
Leuk Lymphoma; 2003 Oct; 44(10):1733-8. PubMed ID: 14692526
[TBL] [Abstract][Full Text] [Related]
5. Serum CA 125 is of clinical value in the staging and follow-up of patients with non-Hodgkin's lymphoma: correlation with tumor parameters and disease activity.
Lazzarino M; Orlandi E; Klersy C; Astori C; Brusamolino E; Corso A; Bellio L; Gargantini L; Morra E; Bernasconi C
Cancer; 1998 Feb; 82(3):576-82. PubMed ID: 9452277
[TBL] [Abstract][Full Text] [Related]
6. CA125 expression in patients with non-Hodgkin's lymphoma.
Wei G; Yuping Z; Jun W; Bing Y; Qiaohua Z
Leuk Lymphoma; 2006 Jul; 47(7):1322-6. PubMed ID: 16923563
[TBL] [Abstract][Full Text] [Related]
7. Serum levels of interleukin-6 and interleukin-10 in Turkish patients with aggressive non-Hodgkin's lymphoma.
Guney N; Soydinc HO; Basaran M; Bavbek S; Derin D; Camlica H; Yasasever V; Topuz E
Asian Pac J Cancer Prev; 2009; 10(4):669-74. PubMed ID: 19827892
[TBL] [Abstract][Full Text] [Related]
8. An improved prognostic parameter for non-Hodgkin's lymphoma based on the combination of three serum tumor markers.
Gui W; Wang T; Wang J; Wang L; He J; Yang B; Zhao Z; Zhang H; Zhang Q
Int J Biol Markers; 2008; 23(4):207-13. PubMed ID: 19199267
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of tumor markers CA 125 and CA 15.3 at diagnosis and during follow-up in non-Hodgkin's lymphoma: study of 200 patients.
Batlle M; Ribera JM; Oriol A; Pastor C; Mate JL; Fernández-Avilés F; Flores A; Millá F; Feliu E
Leuk Lymphoma; 2005 Oct; 46(10):1471-6. PubMed ID: 16194893
[TBL] [Abstract][Full Text] [Related]
10. Usefulness of the epithelial tumor marker CA-125 in non-Hodgkin's lymphoma.
Ozgüroglu M; Turna H; Demir G; Döventas A; Demirelli F; Mandel NM; Büyükünal E; Serdengeçti S; Berkarda B
Am J Clin Oncol; 1999 Dec; 22(6):615-8. PubMed ID: 10597748
[TBL] [Abstract][Full Text] [Related]
11. High serum hepatocyte growth factor level in patients with non-Hodgkin's lymphoma.
Hsiao LT; Lin JT; Yu IT; Chiou TJ; Liu JH; Yen CC; Wang WS; Chen PM
Eur J Haematol; 2003 May; 70(5):282-9. PubMed ID: 12694163
[TBL] [Abstract][Full Text] [Related]
12. Non-Hodgkin's lymphoma of the gastrointestinal tract: a population-based analysis of incidence, geographic distribution, clinicopathologic presentation features, and prognosis. Danish Lymphoma Study Group.
d'Amore F; Brincker H; Grønbaek K; Thorling K; Pedersen M; Jensen MK; Andersen E; Pedersen NT; Mortensen LS
J Clin Oncol; 1994 Aug; 12(8):1673-84. PubMed ID: 8040680
[TBL] [Abstract][Full Text] [Related]
13. Serum-soluble fas level determines clinical symptoms and outcome of patients with aggressive non-Hodgkin's lymphoma.
Hara T; Tsurumi H; Takemura M; Goto H; Yamada T; Sawada M; Takahashi T; Moriwaki H
Am J Hematol; 2000 Aug; 64(4):257-61. PubMed ID: 10911377
[TBL] [Abstract][Full Text] [Related]
14. [Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].
Zhou SY; Shi YK; He XH; Zhang P; Dong M; Huang DZ; Yang JL; Zhang CG; Liu P; Yang S; Feng FY
Ai Zheng; 2005 Apr; 24(4):465-9. PubMed ID: 15820071
[TBL] [Abstract][Full Text] [Related]
15. Bone marrow involvement by non-Hodgkin's lymphoma: the clinical significance of morphologic discordance between the lymph node and bone marrow. Nebraska Lymphoma Study Group.
Conlan MG; Bast M; Armitage JO; Weisenburger DD
J Clin Oncol; 1990 Jul; 8(7):1163-72. PubMed ID: 1694234
[TBL] [Abstract][Full Text] [Related]
16. Serum interleukin-10 in non-Hodgkin's lymphoma: a prognostic factor.
Blay JY; Burdin N; Rousset F; Lenoir G; Biron P; Philip T; Banchereau J; Favrot MC
Blood; 1993 Oct; 82(7):2169-74. PubMed ID: 8400266
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of suppressor of cytokines signalling-3 mRNA expression from patients with non-Hodgkin lymphoma under chemotherapy.
Attia FM; Hassan AM; El-Maraghy NN; Ibrahium GH
Cancer Biomark; 2011-2012; 11(1):41-7. PubMed ID: 22820139
[TBL] [Abstract][Full Text] [Related]
18. Serum CA 125 levels in children with non-Hodgkin's lymphoma.
Kutluk T; Varan A; Erbaş B; Büyükpamukçu M
Pediatr Hematol Oncol; 1999; 16(4):311-9. PubMed ID: 10407867
[TBL] [Abstract][Full Text] [Related]
19. [CA125 in non-Hodgkin's lymphoma].
Liu CJ; Tzeng CH; Liu JH; Chaou SC; Liu JM; Fan S; Hsieh RK; Liu SM; Tiu CM; Liu RS
Zhonghua Yi Xue Za Zhi (Taipei); 1991 Nov; 48(5):382-7. PubMed ID: 1659939
[TBL] [Abstract][Full Text] [Related]
20. Antiphospholipid antibodies may be a new prognostic parameter in aggressive non-Hodgkin's lymphoma.
Bairey O; Blickstein D; Monselise Y; Lahav J; Stark P; Prokocimer M; Nativ HM; Kirgner I; Pazgal I; Shaklai M
Eur J Haematol; 2006 May; 76(5):384-91. PubMed ID: 16466368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]